KALA BIO
KALA
99 hedge funds and large institutions have $79.4M invested in KALA BIO in 2021 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 27 increasing their positions, 23 reducing their positions, and 13 closing their positions.
23% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 13
17% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 23
2% more funds holding
Funds holding: 97 → 99 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% less ownership
Funds ownership: 0.02% → 0.02% (-0%)
54% less capital invested
Capital invested by funds: $171M → $79.4M (-$91.6M)
57% less call options, than puts
Call options by funds: $388K | Put options by funds: $907K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$1M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$621K |
| 3 |
Renaissance Technologies
New York
|
+$578K |
| 4 |
Millennium Management
New York
|
+$432K |
| 5 |
TCM
Towercrest Capital Management
Newtown,
Pennsylvania
|
+$423K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$7M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$1.16M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.04M |
| 4 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
-$920K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$863K |
KALA Hedge Fund Activity: Q3 2021 in Review
99 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in KALA BIO (KALA) for Q3 2021, worth a combined $79.4M — down 54% from $171M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new KALA positions and 13 closed out — a net gain of 3 holders — while 27 added to existing stakes and 23 trimmed.
The largest buyer was State Street, adding an estimated $1M. The largest seller was OrbiMed, cutting an estimated $7M.
- 99 institutional investors held KALA BIO (KALA) as of Q3 2021, up from 97 in Q2 2021.
- Funds reported $79.4M of KALA BIO stock for Q3 2021, down 54% quarter-over-quarter.
- 16 funds opened new KALA BIO positions in Q3 2021 and 13 closed out, a net change of +3 holders.
- The largest KALA BIO buyer in Q3 2021 was State Street, an estimated $1M added.
- The largest KALA BIO seller in Q3 2021 was OrbiMed, an estimated $7M sold.
Based on aggregated 13F filings for Q3 2021.